Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06334133 · ClinicalTrials.gov registry record · Phase 3
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
A Phase 3 study of Diabetes Mellitus, Type 1, sponsored by vTv Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06334133: Recruiting Phase 3 study of Diabetes Mellitus, Type 1, sponsored by vTv Therapeutics.
NCT06334133 is a Phase 3 study of Diabetes Mellitus, Type 1 that is actively recruiting participants, run by vTv Therapeutics. The registered enrollment target is 150 participants, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06334133, a Phase 3 study of Diabetes Mellitus, Type 1, is actively recruiting participants, sponsored by vTv Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Primary Outcome
Number of events of Level 2 or Level 3 hypoglycemia in participants on cadisegliatin vs placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cadisegliatin 800 mg QD
- DRUG Cadisegliatin 800 mg BID
Study Locations (20)
California
- Advanced Metabolic Care & Research Institute, Inc. (AMCR) - Escondido
- MD Studies, Inc - Fountain Valley
- AME Clinical Research - Huntington Beach
- 310 Clinical Research - Inglewood
- Scripps Whittier Diabetes Institute - La Jolla
- Paradigm Clinical Research - Modesto - Modesto
- Amicis Research Center - Northridge
- Velocity Clinical Research - San Bernardino
- Paradigm Clinical Research Centers LLC - San Diego
- Acclaim Clinical Research - San Diego
- Focus Clinical Research - West Hills
Florida
- BayCare Health Systems - Clearwater
- ALL Medical Research, LLC - Cooper City
- Excellence Medical and Research - Miami Gardens
- Metabolic Research Institute, Inc - West Palm Beach
Georgia
- Atlanta Diabetes Associates - Atlanta
- East Coast Institute for Research, LLC - Canton
Arizona
- Scottsdale Clinical Trials - Scottsdale
Arkansas
- Baptist Health Center for Clinical Research - Little Rock
Colorado
- Denver Endocrinology Diabetes and Thyroid Center - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-06-14 |
| Est. Completion | 2026-10 |
| Phase | Phase 3 |
What NCT06334133 shows while recruiting
NCT06334133 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06334133 names 20 study sites across 6 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06334133 about?
NCT06334133 is a clinical study titled "Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes". This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
What is the current status of trial NCT06334133?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2024-06-14. Estimated completion is 2026-10.
What conditions does trial NCT06334133 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT06334133?
The interventions under investigation include: Placebo (DRUG), Cadisegliatin 800 mg QD (DRUG), Cadisegliatin 800 mg BID (DRUG).
Who is sponsoring clinical trial NCT06334133?
This trial is sponsored by vTv Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06334133 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06334133's enrollment target sits among peer trials
150 37th of 118 higher than 78 of 118 other Diabetes Mellitus, Type 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
RECRUITING · Phase 3
-
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
RECRUITING · Phase 3
-
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
RECRUITING · Phase 3
-
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
RECRUITING · Phase 3
-
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
RECRUITING · Phase 3
-
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI